Mesoblast is aiming to get 2012 approval for bone marrow treatment

05/12/2010 | Bloomberg Businessweek

Mesoblast, an Australian company that develops stem cell treatments, has agreed to acquire the remaining shares of Angioblast Systems that it doesn't yet own. The acquisition will give Mesoblast exclusive rights to various treatments, including a stem cell treatment that expands umbilical cord blood used in bone marrow transplants among leukemia patients. Mesoblast hopes to get the treatment approved by 2012.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI